PRESENTATION
Q1 2026 — Presentation
Q1 2026PDF · 31 pages2.4 MB
First-Quarter 2026 Sales and Earnings Merck & Co., Inc., Rahway, N.J., USA April 30, 2026 -- 1 of 31 -- Agenda 2 Strategy and Business Update Robert M. Davis Chairman and Chief Executive Officer Agenda Financial Results and Outlook Caroline Litchfield Executive Vice President and Chief Financial Officer Research Update Dr. Dean Y. Li Executive Vice President and President, Research Laboratories Question & Answer Session -- 2 of 31 -- Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA 3 This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). -- 3 of 31 -- Strategy and Business Update Robert M. Davis Chairman and Chief Executive Officer 4 -- 4 of 31 -- ¹Weber Shandwick/KCR Research, 2020 / AMO 2019 5 $16.3B Q1 Worldwide Sales Strength in Oncology and Animal Health Increasing contributions from new launches +5% nominal +3% ex-exchange Achieved significant pipeline and regulatory progress: • FDA accepted four filings across oncology portfolio including new BLA for ifinatamab deruxtecan1 for priority review in SCLC Oncology • FDA approved once-daily IDVYNSO, a new, two-drug single-tablet regimen of doravirine and islatravir for certain adults with virologically suppressed HIV-1 Infectious Diseases • Presented results from new studies evaluating enlicitide and WINREVAIR at ACC 2026 Cardiometabolic & Respiratory • Initiated pivotal Phase 2b/3 studies evaluating MK-8748, a TIE- 2/VEGF bispecific antibody, in NVAMD Ophthalmology • FDA approved NUMELVI, the first and only second-generation JAK inhibitor for allergic dermatitis in dogs Animal Health 1. In collaboration with Daiichi Sankyo -- 5 of 31 -- 66 Announced strategic acquisition 1 of Terns Pharmaceuticals Adds TERN-701, an investigational next-generation, allosteric TKI for treatment of certain patients with chronic myeloid leukemia Science-driven business development that strengthens and complements hematology pipeline Potential best-in-class profile with opportunity to further improve depth and duration of response in certain patients Multibillion dollar commercial opportunity and growth driver in the next decade, creating shareholder value 1. Transaction expected to close in May -- 6 of 31 -- 7 Executing Business Development Actively pursuing additional science-driven, value-creating transactions Launching New Growth Drivers Expect >20 new growth drivers, almost all of which have blockbuster potential Advancing Diverse & Expansive Pipeline ~80 Phase 3 studies ongoing Transforming our portfolio with next wave of innovation Significant commercial opportunity Potential commercial opportunity of >$70B1 from new growth drivers alone by the mid-2030s 1. Non-risk adjusted annual sales by the mid-2030s -- 7 of 31 -- Financial Results and Outlook Caroline Litchfield Executive Vice President and Chief Financial Officer 8 -- 8 of 31 -- 9 Q1 worldwide performance driven by demand for our innovative portfolio Human Health $14.3B+5% growth +2% ex-exchange $16.3B+5% nominal +3% ex-exchange WORLDWIDE SALES1 Animal Health $1.8B+13% growth +6% ex-exchange 1. Worldwide Sales includes Other Revenue -- 9 of 31 -- Oncology: KEYTRUDA continues to benefit patients and drive growth 10 KEYTRUDA family1 sales of $8.0B increased 8%, driven by strong demand from metastatic indications and robust uptake in earlier-stage cancers ‒ Growth driven by usage in tumors predominantly affecting women, including those with certain breast and cervical cancers ‒ Increased use of KEYTRUDA in combination with enfortumab vedotin in locally advanced or metastatic urothelial cancer ‒ In the U.S., growth benefitted by ~$250M due to timing of wholesaler purchases, as expected ‒ KEYTRUDA QLEX sales of $128M in 1Q26 following launch in 3Q25; permanent J-code effective April 1st 1Q24 1Q25 1Q26 $6.9B +24%2 $8.0B +8%$7.2B +6% Growth rates exclude the impact of foreign exchange 1. KEYTRUDA family includes KEYTRUDA and KEYTRUDA QLEX (available as KEYTRUDA SC in some markets) 2. ~4 percentage points of negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market -- 10 of 31 -- 1Q24 1Q25 1Q26 Oncology: Continued impact for patients across broad portfolio 11 WELIREG sales grew 43%, driven by continued launch uptake in international markets and higher demand in the U.S. Lynparza 1 alliance revenue grew 6%, primarily due to higher demand in the U.S. and many international markets Lenvima 2 alliance revenue declined 2% Growth rates exclude the impact of foreign exchange 1. In collaboration with AstraZeneca 2. In collaboration with Eisai 1Q24 1Q25 1Q26 $312M +8% $292M +7% $341M +6% 1Q24 1Q25 1Q26 $258M +2% $255M +10% $256M -2% $85M +102% $137M +63% $199M +43% -- 11 of 31 -- Vaccines & Infectious Diseases: Protecting lives globally 1Q24 1Q25 1Q26 1Q24 1Q25 1Q26 $1.1B -22% Growth rates exclude the impact of foreign exchange 1. Launched in 3Q24 GARDASIL sales of $1.1B decreased 22%, driven by lower demand in China and Japan, consistent with expectations ‒ In the U.S., sales declined 10% primarily due to the timing of CDC purchases, partially offset by price CAPVAXIVE 1 sales of $142M increased 31% driven by uptake from ongoing launches in certain international markets ‒ In the U.S., growth was driven by increased demand from both retail pharmacies and non- retail customers, partially offset by a reduction in wholesaler inventory $142M +31% $2.2B +17% $1.3B -40% $107M -- 12 of 31 -- Cardiometabolic & Respiratory: Continuing to drive impact for patients with successful ongoing launches WINREVAIR1 sales of $525M driven by continued growth in new patient starts and total prescriptions ‒ In the U.S., >1,600 new patients prescribed and >29,500 total prescriptions dispensed ‒ Ex-U.S., making progress with approvals and reimbursement OHTUVAYRE 2 sales of $131M reflect strong growth in total prescriptions ‒ Sequential sales decline due to Medicare deductible resets and CMS reimbursement change 1Q24 1Q25 1Q26 $1.7B +40% 1Q24 1Q25 1Q26 $131M Growth rates exclude the impact of foreign exchange 1. Launched in 2Q24 2. 1Q26 sales following the closing of the acquisition of Verona Pharma on October 7th , 2025 3. Sales reported by Verona Pharma $280M $525M +87% $71M3 -- 13 of 31 -- Animal Health: Strong growth driven by livestock and companion animal 14 Animal Health sales increased 6% to $1.8B ‒ Livestock sales grew 8%, driven by higher demand for ruminant and poultry products as well as price ‒ Companion Animal sales grew 4% driven by new product launches and price, partially offset by lower demand for other products in portfolio due to lower vet visits 1Q24 1Q25 1Q26 $1.5B +4% 1 $1.6B +10% $1.8B +6% Growth rates exclude the impact of foreign exchange 1. ~3 percentage points of negative impact of foreign exchange due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market -- 14 of 31 -- Q1 2026 non-GAAP financial results summary 1 $ in billions, except LPS / EPS amounts 15 1. The company is providing certain 2026 and 2025 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q1 2026 non-GAAP results include a charge of $9.0 billion related to the acquisition of Cidara Therapeutics 3. Q1 2026 non-GAAP results include a charge of $3.62 per share related to the acquisition of Cidara Therapeutics. 4. Q1 2026 GAAP LPS of $(1.72). Q1 2026 Q1 2025 Change Change Ex-FX Sales $16.3 $15.5 +5% +3% Non-GAAP Gross Margin 81.9% 82.2% -0.3 pts +0.1 pts Non-GAAP Operating Expenses2 $15.2 $6.1 N/M N/M Non-GAAP Tax Rate -43.5% 14.2% N/M N/A Non-GAAP (Loss) / Earnings Per Share3,4 $(1.28) $2.22 N/M N/M -- 15 of 31 -- 16 Updated 2026 financial outlook 1. Guidance does not assume any additional significant potential business development transactions 2. Outlook does not reflect expected ~$5.8B, or ~$2.35 per share, one-time charge for the proposed acquisition of Terns Pharmaceuticals Prior Guidance Updated Guidance Key Assumptions Revenue $65.5B to $67.0B $65.8B to $67.0B • Assumes ~1 percentage point positive impact from FX • Implies +1% to +3% nominal (+0% to +2% ex-FX) Non-GAAP Gross Margin Rate ~82.0% ~82.0% Non-GAAP Operating Expenses1, 2 $35.9B to $36.9B $36.0B to $36.8B • Includes $9B charge related to acquisition of Cidara Other (Income) / Expense ~$1.3B of expense ~$1.3B of expense • Includes financing costs related to acquisitions of Verona and Cidara Tax Rate ~23.5% to 24.5% ~23.5% to 24.5% • Includes impact of non-tax deductible charge for Cidara Shares Outstanding ~2.48B ~2.48B • Assumes ~3B of share repurchases Non-GAAP EPS1,2 $5.00 to $5.15 $5.04 to $5.16 • Includes ~$3.62 negative impact related to upfront charge for acquisition of Cidara • Assumes ~$0.10 positive impact from FX -- 16 of 31 -- Key modeling considerations 17 • Anticipate minimal sales in 2Q given expected seasonality and continued high levels of RSV mAb inventory in marketplace ENFLONSIA KEYTRUDA • In the U.S., expect headwind from timing of wholesaler purchases in 3Q SG&A • Expect expenses to increase over remainder of year due to investment in launches -- 17 of 31 -- Remain committed to balanced capital allocation strategy Q1 Spend ($ in billions) 1 18 Augmented our pipeline and portfolio with value- enhancing business development while investing in our pipeline and business as well as returning cash to shareholders 1. Reflects quarter spend 2. Reflects R&D excluding Business Development Capital allocation order of priority 2 $3.1 $1.0 $2.1 $9.1 $0.9 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase -- 18 of 31 -- Research Update Dr. Dean Y. Li Executive Vice President and President, Research Laboratories 19 -- 19 of 31 -- Important updates across cardiometabolic and respiratory portfolio 20 Enlicitide • Phase 3 results support ambition to bring first approved oral PCSK9i designed to have antibody-like LDL-C lowering to a broad population globally • Percent LDL-C reduction from baseline as demonstrated: WINREVAIR • Totality of evidence from Phase 2 CADENCE study provides strong rationale for Phase 3 development in CpcPH-HFpEF • Robust primary endpoint4 results at 0.3mg/kg dose: • Additional findings from exploratory secondary endpoints at 0.3mg/kg dose include: 2026 AHA/ACC Multisociety Guidelines3 • Updated guidelines support early and aggressive treatment to reduce lifetime cumulative LDL-C exposure and restore concrete targets • Key goals include: – <55 mg/dL for very high risk ASCVD – <70 mg/dL for high risk ASCVD and primary prevention patients with PREVENT score >10 • Most patients with ASCVD will qualify for an LDL-C goal of <55 mg/dL -57.11 -59.62 -58.2 -64.6 1. Per statistical analysis plan 2. Reanalysis (post-hoc) conducted to remove imputed biologically impossible baseline values 3. Blumentahl, et al., (2026) Circulation, 153. Published online March 13, 2026. 4. The primary endpoint was also statistically significant at the 0.7 mg/kg dose 5. The secondary endpoint of 6MWD did not reach statistical significance at the 0.7mg/kg dose, and subsequent secondary endpoints were not eligible to be tested due to the prespecified hierarchical testing strategy 6MWD5 +20.3 meters TTCW5 Prolonged TTCW (HR: 0.18) PVR -1.02 Wood units -- 20 of 31 -- Continuing to advance cancer care with broad portfolio and pipeline 21 KEYTRUDA • KEYNOTE-B96: FDA and EC approved KEYTRUDA in combination with paclitaxel, with or without bevacizumab, for treatment of PD-L1+ cisplatin- resistant ovarian cancer • KEYNOTE-B151: Findings showed perioperative KEYTRUDA in combination with enfortumab vedotin reduced risk of EFS events by 47% and risk of death by 35% vs neoadjuvant chemotherapy2 for treatment of cisplatin-eligible MIBC ‒ Sixth study of KEYTRUDA-based regimen to demonstrate OS in earlier stage cancer − PDUFA date August 17, 2026 I-DXd4 • Announced priority review for BLA filing based on Phase 2 IDeate- Lung01 and Phase 1/2 IDeate-Pan Tumor01 trials for extensive-stage SCLC with disease progression on or after platinum-based chemotherapy − PDUFA date October 10, 2026 WELIREG • LITESPARK-022: WELIREG plus KEYTRUDA demonstrated a 28% reduction in the risk of disease recurrence or death compared to KEYTRUDA alone in adjuvant RCC setting − PDUFA date June 19, 2026 • LITESPARK-011: WELIREG plus Lenvima3 demonstrated a 30% reduction in the risk of disease progression or death versus cabozantinib in previously treated advanced RCC with disease progression on or after anti PD- 1/PD-L1 therapy − PDUFA date October 4, 2026 1. In collaboration with Pfizer and Astellas 2. Regimen versus neoadjuvant chemotherapy (gemcitabine plus cisplatin) and surgery 3. In collaboration with Eisai 4. In collaboration with Daiichi Sankyo -- 21 of 31 -- Terns Pharmaceuticals acquisition 1 expands hematology pipeline 22 Chronic myeloid leukemia • Bone marrow cancer driven by BCR::ABL fusion gene • Advances in treatment have transformed CML to chronic disease that can require life-long treatment • Significant unmet need remains for improved efficacy, safety and convenience • Quality of life and long-term tolerability increasingly important goals as treatment duration extends TERN-701 • Potent, oral, next-generation allosteric BCR::ABL TKI • Highly selective, with a novel binding site • Potential best-in-class efficacy 1. Transaction expected to close in May -- 22 of 31 -- Building on our strong legacy in combatting infectious diseases 23 HIV • FDA and MHLW approved IDVYNSO for treatment of HIV-1 infection in adults who are virologically suppressed • First two-drug regimen without an HIV integrase strand transfer inhibitor to demonstrate non- inferior efficacy and a generally comparable safety profile versus bictegravir / emtricitabine / tenofovir alafenamide RSV • Presented positive top line results for ENFLONSIA for prevention of RSV disease in infants and children under two years of age at increased risk over two seasons based on Phase 3 SMART study at RSV-VW-26 • EC approved for newborns and infants during their first season • Important new treatment option as health needs of adults living with HIV change over time -- 23 of 31 -- Progressing late-stage ophthalmology pipeline 24 MK-8748 • Potential first-in-class bispecific inhibiting VEGF and directly activating Tie2 pathway • Initial Phase 1/2a RIOJA data demonstrated MK- 8748 was well tolerated with no drug-related AEs or SAEs and rapid, sustained structural and functional responses • Initiated two Phase 2b/3 studies, MALBEC and TORRONTES, for treatment of NVAMD Mechanism of action • Antibody binds Tie2 and VEGF aiming to stabilize blood retinal barrier and reduce free VEGF -- 24 of 31 -- Significant late-stage pipeline milestones over next six months 25 1. KEYTRUDA family includes KEYTRUDA and KEYTRUDA QLEX 2. In collaboration with Pfizer and Astellas 3. In collaboration with Daiichi Sankyo 4. In collaboration with Gilead Oncology ASCO Investor Event • Monday, June 1st KEYTRUDA Family 1 • KEYNOTE-B152 PDUFA date August 17 th WELIREG • LITESPARK-022 PDUFA date June 19th • LITESPARK-011 PDUFA date October 4th I-DXd 3 • IDeate-Lung013 PDUFA date October 10 th Cardiometabolic & respiratory WINREVAIR • HYPERION PDUFA date September 21st Enlicitide • CNPV process progressing HIV Islatravir/Lenacapavir4 • Readout of Phase 3 ISLEND-1 and ISLEND-2 trials for HIV treatment Immunology Tulisokibart • PCD in August for Phase 3 ATLAS trial in UC • PCD in May for Phase 2 ATHENA trial in SSc-ILD Ophthalmology MK-3000 • PCD in September for Phase 3 BRUNELLO trial in DME MK-8748 • Readout of Phase 2a RIOJA trial in NVAMD, DME, and RVO -- 25 of 31 -- Q&A Robert M. Davis Chairman and Chief Executive Officer Dr. Dean Y. Li Executive Vice President and President, Research Laboratories Caroline Litchfield Executive Vice President and Chief Financial Officer Peter Dannenbaum Senior Vice President, Investor Relations -- 26 of 31 -- 27 Appendix -- 27 of 31 -- Q1 2026 GAAP financial results summary $ in billions, except LPS / EPS amounts 28 Q1 2026 Q1 2025 Change Change Ex-FX Sales $16.3 $15.5 +5% +3% Operating Expenses (SG&A and R&D)1 $15.3 $6.2 N/M N/M Tax Rate -20.1% 13.9% N/M N/A GAAP (Loss) / Earnings per Share2 $(1.72) $2.01 N/M N/M 1. Q1 2026 GAAP results include a charge of $9.0 billion related to the acquisition of Cidara Therapeutics 2. Q1 2026 GAAP results include a charge of $3.62 per share related to the acquisition of Cidara Therapeutics -- 28 of 31 -- $12.7 $3.8 $8.2 $20.5 $4.8 $0 $3 $6 $9 $12 $15 $18 $21 $24 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase Capital allocation: Trailing twelve months 29 Capital allocation order of priority 2 1 Executing upon balanced capital allocation strategy 1. Reflects R&D excluding Business Development 2. Includes BD payments reflected in operating cash flow Over the past 12 months Committed to the dividend 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026E Dollars per Share +2% +2% +15% +11% +7% +6% +6% +5% +5% +5%Capital investments 2025 to 2029 ~$20B Over 5 years, including more than $12B in the U.S. Well-positioned balance sheet with capacity to fund additional value- enhancing business development opportunities -- 29 of 31 -- Broad and innovative pipeline to address significant unmet medical needs 30 As of April 30, 2026 Phase 3 Oncology MK-1022 (patritumab deruxtecan) 1 Breast MK-1026 (nemtabrutinib) Hematological Malignancies MK-1084 (calderasib) 1 CRC NSCLC MK-2140 (zilovertamab vedotin) Hematological Malignancies MK-2400 (ifinatamab deruxtecan) 1 Esophageal Prostate SCLC (EU) MK-2870 (sacituzumab tirumotecan) 1 Bladder Breast Cervical Endometrial Gastric NSCLC Ovarian MK-1406 Influenza LAGEVRIO (MK-4482) 1,3 COVID-19 (U.S.) MK-8527 HIV-1 PrEP MK-8591A (doravirine + islatravir) HIV-1 Infection (EU) MK-8591D (islatravir + lenacapavir) 1,2 HIV-1 Infection KEYTRUDA (MK-3475) SCLC MK-3543 (bomedemstat) Myeloproliferative Disorders MK-5684 (opevesostat) Prostate MK-5909 (raludotatug deruxtecan) 1 Ovarian LYNPARZA (MK-7339) 1 NSCLC SCLC V940 (intismeran autogene) 1 Melanoma NSCLC Infectious Diseases MK-1022 (patritumab deruxtecan) 1 Biliary Bladder Cervical Endometrial Esophageal Gastric HCC Melanoma NSCLC Ovarian Pancreatic Prostate MK-1084 (calderasib) 1 Solid Tumors MK-2400 (ifinatamab deruxtecan) 1 Biliary Bladder Breast Cervical Endometrial HCC HNSCC Melanoma NSCLC Ovarian Pancreatic Solid Tumors MK-2870 (sacituzumab tirumotecan) 1 Biliary Esophageal Neoplasm Malignant Pancreatic Oncology Infectious Diseases MK-8591B (islatravir + ulonivirine) HIV-1 Infection MK-5475 PH-COPD MK-5884A (ensifentrine + glycopyrrolate) COPD MK-6024 (efinopegdutide) MASH MK-7262 Atherosclerosis WINREVAIR (MK-7962) Pulmonary Hypertension due to Left Heart Disease Cardiometabolic & Respiratory MK-7240 (tulisokibart) Axial Spondyloarthritis Hidradenitis Suppurativa Psoriatic Arthritis Rheumatoid Arthritis Systemic Sclerosis MK-8690 Ulcerative Colitis Immunology MK-3120 Bladder KEYTRUDA (MK-3475) Prostate KEYTRUDA QLEX (MK-3475A) Hematological Malignancies (U.S.) MK-5684 (opevesostat) Breast Endometrial Ovarian MK-5909 (raludotatug deruxtecan) 1 Cervical Endometrial Gastric NSCLC RCC SCLC MK-6070 (gocatamig) 1 SCLC WELIREG (MK-6482) Breast V940 (intismeran autogene) 1 Bladder RCC MK-1167 Alzheimer’s Disease MK-2214 Alzheimer’s Disease Neuroscience Under regulatory review Oncology MK-2400 (ifinatamab deruxtecan)1 SCLC (U.S.) KEYTRUDA (MK-3475) Breast (U.S.) Cisplatin Eligible MIBC (U.S.) Cisplatin Ineligible MIBC (EU, JPN) Ovarian (JPN) KEYTRUDA QLEX (MK-3475A) Breast (U.S.) Cisplatin Eligible MIBC (U.S.) WELIREG (MK-6482) Clear Cell RCC Following Nephrectomy (U.S.) 5 Previously Treated Advanced RCC (U.S., JPN) 1 MK-7240 (tulisokibart) Crohn’s Disease Ulcerative Colitis Immunology Cardiometabolic & Respiratory MK-0616 (enlicitide decanoate) Hypercholesterolemia (U.S.) MK-30004 Diabetic Macular Edema MK-8748 4 Neovascular Age-Related Macular Degeneration Ophthalmology V181 Dengue Fever Virus Vaccines Phase 3 Phase 2 Infectious Diseases ENFLONSIA (MK-1654) Respiratory Syncytial Virus (JPN) Cardiometabolic & Respiratory MK-0616 (enlicitide decanoate) Primary Hypercholesterolaemia or Mixed Dyslipidaemia (EU) WINREVAIR (MK-7962) Pulmonary arterial hypertension (U.S.) 1. Being developed in a collaboration 2. On partial clinical hold for higher doses of islatravir than those used in current clinical trials 3. Available in the U.S. under Emergency Use Authorization 4. Program is in Phase 2/3 studies 5. Under review for combination use with KEYTRUDA or KEYTRUDA QLEX -- 30 of 31 -- 31 6MWD = 6-minute walk distance AE = Adverse event AHA/ACC = American Heart Association/American College of Cardiology ASCVD = Atherosclerotic cardiovascular disease BCR::ABL = Breakpoint Cluster Region – Abelson murine leukemia viral oncogene homolog BLA = Biologics license application CML = Chronic myeloid leukemia CNPV = Commissioner's National Priority Voucher CpcPH-HFpEF = Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction DME = Diabetic macular edema EFS = Event free survival HeFH = Heterozygous familial hypercholesterolemia HIV-1 = Human Immunodeficiency Virus Type 1 I-DXd = Ifinatamab deruxtecan JAK = Janus kinase LDL-C = Low-density lipoprotein cholesterol MAb = Monoclonal antibody Acronyms MIBC = Muscle invasive bladder cancer NVAMD = Neovascular age-related macular degeneration OS = Overall survival PCD = Primary completion date PCSK9i = Proprotein convertase subtilisin/kexin type 9 inhibitor PD-1/PD-L1 = Programmed cell death protein-1/Programmed cell death ligand-1 PVR = Pulmonary vascular resistance RCC = Renal cell carcinoma RSV = Respiratory syncytial virus RVO = Retinal vein occlusion SAE = Serious adverse event SCLC = Small cell lung cancer SSc-ILD = Systemic sclerosis associated interstitial lung disease TIE-2 = Tyrosine kinase with immunoglobulin-like and EGF-like domains 2 TKI = Tyrosine kinase inhibitor TTCW = Time to clinical worsening UC = Ulcerative colitis VEGF = Vascular endothelial growth factor -- 31 of 31 --